Beer: A 12-pack of Health Facts

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

October 2nd 2025

Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

Semaglutide Cardioprotective Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential / image credit John Deanfield, CBE Courtesy of University College London

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

September 24th 2025

Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis

TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.

APOE ε4 and Inflammation Amplify Risk for Memory Decline in Women with Earlier Menopause

TMS: Mediation analysis found that more than half of elinzanetant's sleep benefit occurs independently of nighttime hot flash reduction, challenging VMS-centric models.

Related Content

Weekly Dose Podcast: Arrhythmias as Early Risk Markers, Flu Vaccine Safety, Salt Substitute Use, Preconception CT Risks, and Global Diabetes Care Gaps

Earlier menopause, APOE ε4, and age-related inflammation combine to accelerate memory decline, revealing key factors in women’s Alzheimer disease risk.

October 2nd 2025

Semaglutide CV Effects Appear Independent of Baseline Adiposity, Suggesting Disease-Modifying Potential

Today's episode highlights arrhythmias as CVD risk markers, influenza vaccine safety, salt substitute use, preconception CT scan risks, and global diabetes care gaps.

Weekly Dose Podcast: Depression Risk After Chronic Illness, Vaginal Estradiol Safety, GLP-1 Updates, Cancer Risk Reduction, and Cardiovascular Outcomes

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

September 24th 2025

Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis

TMS: New data pooled across clinical trials confirm elinzanetant’s consistent efficacy, safety, and sleep benefits across diverse populations of menopausal women.